New packaging solutions for life sciences, all at PACK EXPO in Chicago
Discover new packaging solutions from hundreds of suppliers specializing in life sciences, all under one roof at PACK EXPO International in Chicago.

Cannabis Derivative Inches Toward FDA Approval

New cannabidiol-based drug shows promising results in Phase 3 trial for treating Lennox-Gastaut syndrome.

Cannabis Plant / Photo: GW Pharmaceuticals
Cannabis Plant / Photo: GW Pharmaceuticals

A recent Forbes article says British biotech company GW Pharmaceuticals is seeking FDA approval on their drug, Epidiolex. The drug is cannabidiol-based and used to treat Lennox-Gastaut syndrome, a rare form of epilepsy in children. Results from a Phase 3 clinical trial show that children treated with 20mg of Epidiolex saw a 47% decrease in seizures, versus a 17% drop in placebo patients.

GW Pharma’s next step is seeking approval from the FDA; they plan to submit a New Drug Application in the first half of 2017. Should Epidiolex gain FDA approval, it would be the first plant-derived cannabinoid approved in the U.S., which means the DEA would be legally obligated to reschedule the drug within 90 days. However, marijuana would not be rescheduled since the DEA insists it has no medical benefits. It should be noted that the US government has medical patents on medicinal marijuana.

Explore new technology from hundreds of life sciences suppliers.
At PACK EXPO International, you’ll find innovations from hundreds of exhibitors that specialize in pharmaceuticals, biologics, nutraceuticals, medical devices and more. No other show delivers as many solutions to keep your products safe and effective.
Read More
Explore new technology from hundreds of life sciences suppliers.